Alexion at an excellent entry point, says RW Baird Baird is increasingly confident in Alexion's Solaris prospects both near and long-term. The firm also noted the company's robust pipeline and current valuation and remains buyers of the shares for a recovery into the $125 range. Shares are Outperform rated.
Alexion announces $500M share repurchase program Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.